Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biomodulina T
- Development stage
- Unknown
- Lead developer
- BIOLONG
- Modality
- Peptides
- Administration
- Intramuscular, Intravenous, Sublingual
01
Overview
Biomodulina T (InmunyVital) is a biological immunomodulator composed of a polypeptide fraction derived from the bovine thymus. Developed and manufactured in Cuba by the National Center for Biopreparations (BioCen), it is designed to restore and enhance immune function, particularly in the context of immunosenescence and secondary immunodeficiencies. The drug acts by stimulating the thymus gland and promoting the differentiation, maturation, and proliferation of T lymphocytes. Clinical evidence indicates that Biomodulina T increases the population of naïve CD4+ T cells and stem cell-like memory CD8+ T cells while reducing the frequency of exhausted PD-1+ T cells and terminally differentiated EMRA T cells. It is approved in Cuba for the treatment of recurrent respiratory infections in the elderly and has been investigated as an adjuvant in cancer immunotherapy (e.g., with CIMAvax-EGF) and for the prevention of severe COVID-19.
- Brand names
- InmunyVitalBiomodulina T
- Other names
- Biomodulina-TBT
Beyond the preview
Go deeper on Biomodulina T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biomodulina T.